PE20020518A1 - FORMULATION IN INHALABLE SOLUTION WITH A TIOTROPE SALT - Google Patents
FORMULATION IN INHALABLE SOLUTION WITH A TIOTROPE SALTInfo
- Publication number
- PE20020518A1 PE20020518A1 PE2001001072A PE2001001072A PE20020518A1 PE 20020518 A1 PE20020518 A1 PE 20020518A1 PE 2001001072 A PE2001001072 A PE 2001001072A PE 2001001072 A PE2001001072 A PE 2001001072A PE 20020518 A1 PE20020518 A1 PE 20020518A1
- Authority
- PE
- Peru
- Prior art keywords
- salt
- formulation
- tiotrope
- solvent
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA FORMULACION LIQUIDA EXENTA DE GAS PROPULSOR QUE COMPRENDE: a) DE 0,0005% Y 5% EN PESO DE UNA SAL DE TIOTROPIO; b) UNA SUSTANCIA ACTIVA SELECCIONADA DE AGENTES ANTIALERGICOS, ANTIHISTAMINICOS, ESTEROIDES Y/O AGONISTAS DE LEUCOTRIENOS; c) AGUA O UNA MEZCLA DE AGUA Y ETANOL COMO DISOLVENTE ESTANDO DISUELTA EN ELLA POR LO MENOS O LA SAL DE TIOTROPIO; d) pH ENTRE 2,0 Y 4,5; e) AGENTE CONSERVANTE Y f) UN COMPUESTOS FORMADOR DE COMPLEJO Y/O UN ESTABILIZADOR Y/O UN CO-DISOLVENTE U OTRAS SUSTANCIAS AUXILIARES Y ADITIVAS JUNTO CON EL AGENTE CONSERVANTE. LA FORMULACION ES UTIL PARA EL TRATAMIENTO DEL ASMA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (EPOC)IT REFERS TO A LIQUID FORMULATION FREE OF PROPELLING GAS, INCLUDING: a) 0.0005% AND 5% BY WEIGHT OF A THOTROPE SALT; b) A SELECTED ACTIVE SUBSTANCE FROM ANTI-ALLERGIC, ANTI-HISTAMINE, STEROID AND / OR LEUKOTRIEN AGONISTS; c) WATER OR A MIXTURE OF WATER AND ETHANOL AS A SOLVENT BEING DISSOLVED IN IT AT LEAST OR THE SALT OF TIOTROPE; d) pH BETWEEN 2.0 AND 4.5; e) PRESERVING AGENT AND f) A COMPLEX FORMING COMPOUND AND / OR A STABILIZER AND / OR A CO-SOLVENT OR OTHER AUXILIARY SUBSTANCES AND ADDITIVES TOGETHER WITH THE PRESERVATIVE AGENT. THE FORMULATION IS USEFUL FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10054042 | 2000-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020518A1 true PE20020518A1 (en) | 2002-07-12 |
Family
ID=7661727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001072A PE20020518A1 (en) | 2000-10-31 | 2001-10-29 | FORMULATION IN INHALABLE SOLUTION WITH A TIOTROPE SALT |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1335729A2 (en) |
| JP (1) | JP4559703B2 (en) |
| KR (1) | KR100983208B1 (en) |
| CN (1) | CN1237970C (en) |
| AR (1) | AR038765A1 (en) |
| AU (2) | AU2174102A (en) |
| BG (1) | BG66425B1 (en) |
| BR (1) | BR0115016A (en) |
| CA (1) | CA2427583C (en) |
| CZ (1) | CZ305033B6 (en) |
| DE (1) | DE10152369A1 (en) |
| EA (1) | EA009068B1 (en) |
| EC (1) | ECSP034570A (en) |
| EE (1) | EE05343B1 (en) |
| HK (1) | HK1060569A1 (en) |
| HR (1) | HRP20030337A2 (en) |
| HU (1) | HUP0301377A3 (en) |
| IL (2) | IL155676A0 (en) |
| ME (1) | ME00242B (en) |
| MX (1) | MXPA03003750A (en) |
| MY (1) | MY132777A (en) |
| NO (1) | NO332524B1 (en) |
| NZ (1) | NZ526024A (en) |
| PE (1) | PE20020518A1 (en) |
| PL (1) | PL361001A1 (en) |
| SA (1) | SA01220503B1 (en) |
| SK (1) | SK288031B6 (en) |
| TW (1) | TWI296934B (en) |
| UA (1) | UA76435C2 (en) |
| UY (1) | UY26991A1 (en) |
| WO (1) | WO2002036591A2 (en) |
| YU (1) | YU33103A (en) |
| ZA (1) | ZA200303045B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9519501A (en) | 2000-04-28 | 2001-11-12 | Kosan Biosciences Inc | Production of polyketides |
| US20030235538A1 (en) | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| AU2004280638A1 (en) * | 2003-10-09 | 2005-04-21 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| SE0303269L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medical product |
| CN101128196B (en) * | 2005-03-16 | 2013-01-02 | Meda制药有限及两合公司 | Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| WO2007140285A2 (en) * | 2006-05-26 | 2007-12-06 | Dey, L.P. | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
| CN100446770C (en) * | 2007-01-10 | 2008-12-31 | 上海现代药物制剂工程研究中心有限公司 | Water aerosol containing beclomethasone dipropionate |
| TR200907237A2 (en) * | 2009-09-23 | 2011-04-21 | Bi̇lgi̇ç Mahmut | Tiotropium dry powder combination |
| WO2020019953A1 (en) * | 2018-07-26 | 2020-01-30 | 四川海思科制药有限公司 | Aerosol pharmaceutical composition containing a glycopyrrolate salt, preparation method therefor, and uses thereof |
| WO2020019952A1 (en) * | 2018-07-26 | 2020-01-30 | 四川海思科制药有限公司 | Aerosol pharmaceutical composition containing glycopyrrolate salt and indacaterol salt, preparation method therefor, and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| DE4203306A1 (en) * | 1992-02-06 | 1993-08-12 | Ig Spruehtechnik Gmbh | ASTHMA OR PULMONAL AEROSOL PREPARATIONS WITH LECITHIN |
| MX9800125A (en) * | 1995-06-27 | 1998-03-31 | Boehringer Ingelheim Kg | New, stable medicinal compositions for generating propellant-free aerosols. |
| US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| WO1997046243A1 (en) * | 1996-06-04 | 1997-12-11 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
| DE19653969A1 (en) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | New aqueous pharmaceutical preparation for the production of propellant-free aerosols |
| JPH10298107A (en) * | 1997-04-25 | 1998-11-10 | Taisho Pharmaceut Co Ltd | Pharmaceutical composition |
| CN1150890C (en) * | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | Medicinal aerosol formulations |
| DE19847968A1 (en) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
-
2001
- 2001-10-24 YU YU33103A patent/YU33103A/en unknown
- 2001-10-24 NZ NZ526024A patent/NZ526024A/en not_active IP Right Cessation
- 2001-10-24 PL PL01361001A patent/PL361001A1/en not_active Application Discontinuation
- 2001-10-24 ME MEP-2008-407A patent/ME00242B/en unknown
- 2001-10-24 IL IL15567601A patent/IL155676A0/en unknown
- 2001-10-24 UA UA2003054960A patent/UA76435C2/en unknown
- 2001-10-24 EA EA200300483A patent/EA009068B1/en not_active IP Right Cessation
- 2001-10-24 WO PCT/EP2001/012296 patent/WO2002036591A2/en active IP Right Grant
- 2001-10-24 SK SK526-2003A patent/SK288031B6/en not_active IP Right Cessation
- 2001-10-24 KR KR1020037006001A patent/KR100983208B1/en active IP Right Grant
- 2001-10-24 CZ CZ2003-1487A patent/CZ305033B6/en not_active IP Right Cessation
- 2001-10-24 EP EP01992710A patent/EP1335729A2/en not_active Ceased
- 2001-10-24 JP JP2002539350A patent/JP4559703B2/en not_active Expired - Lifetime
- 2001-10-24 HU HU0301377A patent/HUP0301377A3/en unknown
- 2001-10-24 BR BR0115016-2A patent/BR0115016A/en active Pending
- 2001-10-24 CA CA002427583A patent/CA2427583C/en not_active Expired - Fee Related
- 2001-10-24 AU AU2174102A patent/AU2174102A/en active Pending
- 2001-10-24 CN CNB018183271A patent/CN1237970C/en not_active Expired - Lifetime
- 2001-10-24 EE EEP200300202A patent/EE05343B1/en unknown
- 2001-10-24 AU AU2002221741A patent/AU2002221741B2/en not_active Expired
- 2001-10-24 MX MXPA03003750A patent/MXPA03003750A/en active IP Right Grant
- 2001-10-24 DE DE10152369A patent/DE10152369A1/en not_active Withdrawn
- 2001-10-29 MY MYPI20014987A patent/MY132777A/en unknown
- 2001-10-29 PE PE2001001072A patent/PE20020518A1/en active IP Right Grant
- 2001-10-29 UY UY26991A patent/UY26991A1/en not_active Application Discontinuation
- 2001-10-29 TW TW090126752A patent/TWI296934B/en not_active IP Right Cessation
- 2001-10-31 AR ARP010105088A patent/AR038765A1/en not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 2001-11-03 SA SA01220503A patent/SA01220503B1/en unknown
-
2003
- 2003-04-16 BG BG107726A patent/BG66425B1/en active Active
- 2003-04-17 ZA ZA200303045A patent/ZA200303045B/en unknown
- 2003-04-28 HR HR20030337A patent/HRP20030337A2/en not_active Application Discontinuation
- 2003-04-28 EC EC2003004570A patent/ECSP034570A/en unknown
- 2003-04-29 NO NO20031914A patent/NO332524B1/en not_active IP Right Cessation
- 2003-04-30 IL IL155676A patent/IL155676A/en active IP Right Grant
-
2004
- 2004-05-20 HK HK04103587A patent/HK1060569A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120023A1 (en) | PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST ONE SURFACE-ACTIVE SUBSTANCE | |
| PE20001226A1 (en) | LIQUID FORMULATION WITH FORMOTEROL, SUITABLE FOR STORAGE | |
| PE20020518A1 (en) | FORMULATION IN INHALABLE SOLUTION WITH A TIOTROPE SALT | |
| BRPI1006790B8 (en) | method for developing a liquid pharmaceutical composition to be applied to the skin as a foam and composition suitable for topical use | |
| Jaenke | Delayed and progressive myocardial lesions after adriamycin administration in the rabbit | |
| PE20070643A1 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING BUPRENORPHINE | |
| PE20121396A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING GLYCOPYRONIUM BROMIDE AND FORMOTEROL | |
| PE20190318A1 (en) | ORALLY ADMINISTRABLE COMPOSITION | |
| PE20081361A1 (en) | PHARMACEUTICAL COMPOSITIONS OF CLONAZEPAM AND METHODS OF USE OF THE SAME | |
| JPH08503689A (en) | Novel composition based on taxoid | |
| MX2013001749A (en) | Compositions and methods for treating cardiovascular disease. | |
| AR040881A1 (en) | FORMULATION OF HUMAN ANTIBODIES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH TNF-ALFA | |
| RU2011125550A (en) | OIL-IN-WATER TYPE EMULSION FOR TOPICAL APPLICATION IN DERMATOLOGY | |
| AR098830A2 (en) | WATERPROOF SUSPENSIONS STABILIZED FOR PARENTERAL ADMINISTRATION | |
| AR086115A1 (en) | IMPROVED PARENTERAL FORMULATIONS OF LIPOFIL PHARMACEUTICAL AGENTS AND METHODS FOR THE PREPARATION AND USE OF THE SAME | |
| BRPI0612428A2 (en) | hygroscopic pharmaceutical composition, foamy pharmaceutical vehicle and foamy pharmaceutical composition | |
| BRPI0413957A (en) | process for preparing water soluble diterpenes, aqueous solution and their applications | |
| BRPI0913326C1 (en) | topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in aqueous suspension and a water miscible organic solvent | |
| MXPA01000601A (en) | Stabilized pharmaceutical composition in lyophilized form. | |
| Caruso-Neves et al. | Angiotensin-(1–7) modulates the ouabain-insensitive Na+-ATPase activity from basolateral membrane of the proximal tubule | |
| BRPI0416650A (en) | stable liposome composition for the application of a pharmaceutical agent, sterile and stable liposome composition for the application of a pharmaceutical agent method for producing a stable liposome composition for the application of a pharmaceutical agent, pharmaceutical composition, use of a composition liposome composition, device for containing a stable liposome composition, kit for applying a pharmaceutical agent to a patient, method for increasing the stability of liposome compositions, method for identifying a phase stable liposome composition, liposome composition and phase-stable liposome composition | |
| BR112012015016A8 (en) | PHARMACEUTICAL FORMULATION, ENTERAL PHARMACEUTICAL DOSAGE FORM AND USE OF A FORMULATION | |
| Liu et al. | Hydroxylation of multi-walled carbon nanotubes reduces their cytotoxicity by limiting the activation of mitochondrial mediated apoptotic pathway | |
| ATE350024T1 (en) | LIQUID PREPARATION CONTAINING TOBRAMYCIN | |
| PE20030092A1 (en) | FORMULATION OF AN INHALATION SOLUTION WITH A TIOTROPE SALT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |